羟乙基淀粉抗肿瘤纳米药物研究进展  

Research Progress of Hydroxyethyl Starch-Based Cancer Nanomedicine

作　　者：李峥 徐辉碧[1,2] 杨祥良[1,2] 李子福[1,2] LI Zheng;XU Huibi;YANG Xianghang;LI Zifu(College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China;National Engineering Research Center for Nanomedicine, Huazhong University of Science and Technology, Wuhan 430075, China)

机构地区：[1]华中科技大学生命科学与技术学院,武汉430074 [2]华中科技大学国家纳米药物工程技术研究中心,武汉430074

出　　处：《医药导报》2018年第6期679-689,共11页Herald of Medicine

基　　金：国家自然科学基金资助项目(31700867)

摘　　要：羟乙基淀粉(HES)是临床上常用的血浆扩容剂,具有优异的水溶性、生物相容性及安全性。因其独特的生物学特性,HES可用于肿瘤诊疗药物的体内靶向输送。通过耦联或包埋等方式,HES可以增加药物水溶性及稳定性,延长半衰期,提高肿瘤靶向性,减少正常组织药物摄取并降低毒副作用。HES丰富的羟基官能团还可用于纳米药物表面修饰,实现多功能联合给药。HES在抗肿瘤纳米药物基础研究与临床转化具有巨大潜力。With excellent water solubility,biocompatibility and safety,hydroxyethyl starch（HES） has been widely used as clinical plasma volume expander for over 50 years. Because of the unique biological properties,HES can be used for invivo tumor-targeted delivery of anti-tumor drugs. Via conjugation or encapsulation,HES can increase the aqueous solubility and stability of the drug,thereby extending the half-life time,improving drug tumor accumulation,and reducing the toxicity and side effects of the drug. Abundant hydroxyl groups on the surface of HES can also be used for surface modification to achieve combinational therapies. Therefore,HES possesses significant potential for anti-tumor nanomedicine and clinical translation.

关 键 词：羟乙基淀粉 抗肿瘤纳米药物 药物递送 

分 类 号：R945[医药卫生—微生物与生化药学]